BIOA Valuation

BIOAGE Labs Inc

Add to Watchlist

Advanced Chart

4.740

+0.09(1.935%)1D

Overview
Forecast
Valuation
Earnings

BIOA Relative Valuation

BIOA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BIOA is overvalued; if below, it's undervalued.

Historical Valuation

BIOAGE Labs Inc (BIOA) is now in the Fair zone, suggesting that its current forward PS ratio of 37.01 is considered Fairly compared with the five-year average of -2.95. The fair price of BIOAGE Labs Inc (BIOA) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：4.65

Fair

-2.16

Trailing

Forward

1.32

EV/EBITDA

BIOAGE Labs Inc. (BIOA) has a current EV/EBITDA of 1.32. The 5-year average EV/EBITDA is 0.20. The thresholds are as follows: Strongly Undervalued below -6.48, Undervalued between -6.48 and -3.14, Fairly Valued between 3.54 and -3.14, Overvalued between 3.54 and 6.88, and Strongly Overvalued above 6.88. The current Forward EV/EBITDA of 1.32 falls within the Historic Trend Line -Fairly Valued range.

1.49

EV/EBIT

BIOAGE Labs Inc. (BIOA) has a current EV/EBIT of 1.49. The 5-year average EV/EBIT is 0.44. The thresholds are as follows: Strongly Undervalued below -6.18, Undervalued between -6.18 and -2.87, Fairly Valued between 3.76 and -2.87, Overvalued between 3.76 and 7.07, and Strongly Overvalued above 7.07. The current Forward EV/EBIT of 1.49 falls within the Historic Trend Line -Fairly Valued range.

37.01

BIOAGE Labs Inc. (BIOA) has a current PS of 37.01. The 5-year average PS is 25.20. The thresholds are as follows: Strongly Undervalued below -28.65, Undervalued between -28.65 and -1.72, Fairly Valued between 52.12 and -1.72, Overvalued between 52.12 and 79.04, and Strongly Overvalued above 79.04. The current Forward PS of 37.01 falls within the Historic Trend Line -Fairly Valued range.

-3.37

P/OCF

BIOAGE Labs Inc. (BIOA) has a current P/OCF of -3.37. The 5-year average P/OCF is -3.03. The thresholds are as follows: Strongly Undervalued below -6.88, Undervalued between -6.88 and -4.95, Fairly Valued between -1.11 and -4.95, Overvalued between -1.11 and 0.82, and Strongly Overvalued above 0.82. The current Forward P/OCF of -3.37 falls within the Historic Trend Line -Fairly Valued range.

-2.27

P/FCF

BIOAGE Labs Inc. (BIOA) has a current P/FCF of -2.27. The 5-year average P/FCF is -3.43. The thresholds are as follows: Strongly Undervalued below -8.04, Undervalued between -8.04 and -5.73, Fairly Valued between -1.13 and -5.73, Overvalued between -1.13 and 1.18, and Strongly Overvalued above 1.18. The current Forward P/FCF of -2.27 falls within the Historic Trend Line -Fairly Valued range.

BIOAGE Labs Inc (BIOA) has a current Price-to-Book (P/B) ratio of 0.57. Compared to its 3-year average P/B ratio of 0.62 , the current P/B ratio is approximately -8.40% higher. Relative to its 5-year average P/B ratio of 0.62, the current P/B ratio is about -8.40% higher. BIOAGE Labs Inc (BIOA) has a Forward Free Cash Flow (FCF) yield of approximately -33.00%. Compared to its 3-year average FCF yield of -28.64%, the current FCF yield is approximately 15.23% lower. Relative to its 5-year average FCF yield of -28.64% , the current FCF yield is about 15.23% lower.

0.57

P/B

Median3y

0.62

Median5y

0.62

-33.00

FCF Yield

Median3y

-28.64

Median5y

-28.64

Competitors Valuation Multiple

The average P/S ratio for BIOA's competitors is 16.18, providing a benchmark for relative valuation. BIOAGE Labs Inc Corp (BIOA) exhibits a P/S ratio of 37.01, which is 128.77% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Tevogen Bio Holdings Inc

Loss

175.07M

CRBU.O

Caribou Biosciences Inc

Elicio Therapeutics Inc

Performance Decomposition

Market capitalization of BIOA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of BIOA in the past 1 year is driven by Unknown.